APA
Ricart A. D., Ashton E. A., Cooney M. M., Sarantopoulos J., Brell J. M., Feldman M. A., Ruby K. E., Matsuda K., Munsey M. S., Medina G., Zambito A., Tolcher A. W. & Remick S. C. (20111122). A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors. : Cancer chemotherapy and pharmacology.
Chicago
Ricart Alejandro D, Ashton Edward A, Cooney Matthew M, Sarantopoulos John, Brell Joanna M, Feldman Maria A, Ruby Kale E, Matsuda Kazuko, Munsey Mark S, Medina Gerardo, Zambito Angela, Tolcher Anthony W and Remick Scot C. 20111122. A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors. : Cancer chemotherapy and pharmacology.
Harvard
Ricart A. D., Ashton E. A., Cooney M. M., Sarantopoulos J., Brell J. M., Feldman M. A., Ruby K. E., Matsuda K., Munsey M. S., Medina G., Zambito A., Tolcher A. W. and Remick S. C. (20111122). A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors. : Cancer chemotherapy and pharmacology.
MLA
Ricart Alejandro D, Ashton Edward A, Cooney Matthew M, Sarantopoulos John, Brell Joanna M, Feldman Maria A, Ruby Kale E, Matsuda Kazuko, Munsey Mark S, Medina Gerardo, Zambito Angela, Tolcher Anthony W and Remick Scot C. A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors. : Cancer chemotherapy and pharmacology. 20111122.